{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:09:06Z","timestamp":1790744946907,"version":"4.1.0"},"reference-count":153,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union","award":["101097094-ELMUMY"],"award-info":[{"award-number":["101097094-ELMUMY"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The DNA damage response (DDR) network and the mitogen-activated protein kinase (MAPK) signaling pathway are crucial mechanisms for the survival of all living beings. An accumulating body of evidence suggests that there is crosstalk between these two systems, thus favoring the appropriate functioning of multi-cellular organisms. On the other hand, aberrations within these mechanisms are thought to play a vital role in the onset and progression of several diseases, including cancer, as well as in the emergence of drug resistance. Here, we provide an overview of the current knowledge regarding alterations in the DDR machinery and the MAPK signaling pathway as well as abnormalities in the DDR\/MAPK functional crosstalk in multiple myeloma, the second most common hematologic malignancy. We also present the latest advances in the development of anti-myeloma drugs targeting crucial DDR- and MAPK-associated molecular components. These data could potentially be exploited to discover new therapeutic targets and effective biomarkers as well as for the design of novel clinical trials. Interestingly, they might provide a new approach to increase the efficacy of anti-myeloma therapy by combining drugs targeting the DDR network and the MAPK signaling pathway.<\/jats:p>","DOI":"10.3390\/ijms25136991","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T05:11:39Z","timestamp":1719465099000},"page":"6991","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5771-5352","authenticated-orcid":false,"given":"Panagiotis","family":"Malamos","sequence":"first","affiliation":[{"name":"Institute of Chemical Biology, National Hellenic Research Foundation, 116 35 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Papanikolaou","sequence":"additional","affiliation":[{"name":"Institute of Chemical Biology, National Hellenic Research Foundation, 116 35 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 115 28 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 115 28 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 115 28 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-1329","authenticated-orcid":false,"given":"Vassilis L.","family":"Souliotis","sequence":"additional","affiliation":[{"name":"Institute of Chemical Biology, National Hellenic Research Foundation, 116 35 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple Myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple Myeloma","volume":"397","author":"Pawlyn","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.12703\/r\/11-34","article-title":"Monoclonal Gammopathy of Undetermined Significance: Evaluation, Risk Assessment, Management, and Beyond","volume":"11","author":"Abeykoon","year":"2022","journal-title":"Fac. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","article-title":"From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells","volume":"78","author":"Spaan","year":"2018","journal-title":"Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/bloodadvances.2017007609","article-title":"Obesity and Risk of Monoclonal Gammopathy of Undetermined Significance and Progression to Multiple Myeloma: A Population-Based Study","volume":"1","author":"Thordardottir","year":"2017","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/bloodadvances.2023011608","article-title":"Dietary Risk Factors for Monoclonal Gammopathy of Undetermined Significance in a Racially Diverse Population","volume":"8","author":"Joseph","year":"2024","journal-title":"Blood Adv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00277-021-04400-7","article-title":"Risk Factors for Monoclonal Gammopathy of Undetermined Significance: A Systematic Review","volume":"100","author":"Ulbricht","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/BLCTT.S136447","article-title":"Smoldering Multiple Myeloma: Prevalence and Current Evidence Guiding Treatment Decisions","volume":"8","author":"Blum","year":"2018","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41408-022-00719-0","article-title":"Smoldering Multiple Myeloma Current Treatment Algorithms","volume":"12","author":"Rajkumar","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40164-022-00259-0","article-title":"Progression Patterns in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Outcome: A Cohort Study in 42 Patients","volume":"11","author":"Tahiru","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3324\/haematol.2021.278519","article-title":"2021 European Myeloma Network Review and Consensus Statement on Smoldering Multiple Myeloma: How to Distinguish (and Manage) Dr. Jekyll and Mr. Hyde","volume":"106","author":"Musto","year":"2021","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple Myeloma: The (r)Evolution of Current Therapy and a Glance into Future","volume":"10","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple Myeloma: 2022 Update on Diagnosis, Risk-Stratification and Management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.3390\/curroncol30050334","article-title":"Management of Multiple Myeloma: A Review for General Practitioners in Oncology","volume":"30","author":"Monteith","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"McKenzie, F., Gazz\u00e9, G., Hewitt, J., Kolm, K., Pollock, D., Rowland, S., and Crosbie, T. (2022). Canadian Perspectives in Multiple Myeloma on the Use of Steroids in Clinical Practice Based on Patient and Healthcare Provider Interviews. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1061417"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Poczta, A., Rogalska, A., and Marczak, A. (2021). Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies\u2014Current Research and Clinical Approaches. J. Clin. Med., 10.","DOI":"10.3390\/jcm10091841"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1097\/HS9.0000000000000350","article-title":"Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma","volume":"4","author":"Swan","year":"2020","journal-title":"Hemasphere"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14740338.2019.1615051","article-title":"A Comparative Safety Review of Histone Deacetylase Inhibitors for the Treatment of Myeloma","volume":"18","author":"Beksac","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Li, J., Jia, Z., Wang, R., Xiao, B., Cai, Y., Zhu, T., Wang, W., Zhang, X., Fan, S., and Fan, X. (2024). Activated Interferon Response from DNA Damage in Multiple Myeloma Cells Contributes to the Chemotherapeutic Effects of Anthracyclines. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1357996"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"C451","DOI":"10.1152\/ajpcell.00286.2019","article-title":"Proteasome Inhibition in Multiple Myeloma: Lessons for Other Cancers","volume":"318","author":"Martini","year":"2020","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mina\u0159\u00edk, J., and \u0160ev\u010d\u00edkov\u00e1, S. (2022). Immunomodulatory Agents for Multiple Myeloma. Cancers, 14.","DOI":"10.3390\/cancers14235759"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jtct.2022.06.013","article-title":"High Dose (Conditioning) Regimens Used Prior to Autologous Stem Cell Transplantation in Multiple Myeloma","volume":"28","author":"Ali","year":"2022","journal-title":"Transplant. Cell Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"De Luca, F., Allegra, A., Di Chio, C., Previti, S., Zappal\u00e0, M., and Ettari, R. (2023). Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043136"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T Therapies in Multiple Myeloma: Unleashing the Future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ajh.26379","article-title":"Chimeric Antigen Receptor T-Cells, Bispecific Antibodies, and Antibody-Drug Conjugates for Multiple Myeloma: An Update","volume":"97","author":"Lakshman","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy Bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-Genome Sequencing Reveals Progressive versus Stable Myeloma Precursor Conditions as Two Distinct Entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Aksenova, A.Y., Zhuk, A.S., Lada, A.G., Zotova, I.V., Stepchenkova, E.I., Kostroma, I.I., Gritsaev, S.V., and Pavlov, Y.I. (2021). Genome Instability in Multiple Myeloma: Facts and Factors. Cancers, 13.","DOI":"10.3390\/cancers13235949"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/em.22087","article-title":"Mechanisms of DNA Damage, Repair and Mutagenesis","volume":"58","author":"Chatterjee","year":"2017","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mavroeidi, D., Georganta, A., Panagiotou, E., Syrigos, K., and Souliotis, V.L. (2024). Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202401.1750.v1"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.21037\/atm-20-2920","article-title":"Alterations of DNA Damage Repair in Cancer: From Mechanisms to Applications","volume":"8","author":"Jiang","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-141042","article-title":"Base Excision Repair and Homologous Recombination Pathway Intermediates Drive Genomic Instability and Evolution in Myeloma","volume":"136","author":"Liao","year":"2020","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood.V120.21.3981.3981","article-title":"The Polymorphisms of Base Excision Repair Genes Influence the Prognosis of Multiple Myeloma","volume":"120","author":"Ushie","year":"2012","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41408-018-0129-9","article-title":"Role of Apurinic\/Apyrimidinic Nucleases in the Regulation of Homologous Recombination in Myeloma: Mechanisms and Translational Significance","volume":"8","author":"Kumar","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ko, H.L., and Ren, E.C. (2012). Functional Aspects of PARP1 in DNA Repair and Transcription. Biomolecules, 2.","DOI":"10.3390\/biom2040524"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3324\/haematol.2022.282399","article-title":"PARP1 and POLD2 as Prognostic Biomarkers for Multiple Myeloma in Autologous Stem Cell Transplant","volume":"108","author":"Thomas","year":"2023","journal-title":"Haematologica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3324\/haematol.2019.240713","article-title":"Exploiting MYC-Induced PARPness to Target Genomic Instability in Multiple Myeloma","volume":"106","author":"Caracciolo","year":"2021","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/leu.2017.182","article-title":"Nucleotide Excision Repair Is a Potential Therapeutic Target in Multiple Myeloma","volume":"32","author":"Szalat","year":"2017","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/10428190290006215","article-title":"Mismatch Repair Gene Expression in Malignant Lymphoproliferative Disorders of B-Cell Origin","volume":"43","author":"Kotoula","year":"2002","journal-title":"Leuk. Lymphoma"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/modpathol.3800590","article-title":"HMLH1 and MGMT Inactivation as a Mechanism of Tumorigenesis in Monoclonal Gammopathies","volume":"19","author":"Martin","year":"2006","journal-title":"Mod. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood-2007-05-089193","article-title":"Dysfunctional Homologous Recombination Mediates Genomic Instability and Progression in Myeloma","volume":"113","author":"Shammas","year":"2009","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/bmt.2009.335","article-title":"Genetic Polymorphisms Associated with Outcome in Multiple Myeloma Patients Receiving High-Dose Melphalan","volume":"45","author":"Dumontet","year":"2010","journal-title":"Bone Marrow Transpl."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1016\/j.bbmt.2019.12.203","article-title":"Overcoming Melphalan Resistance by Targeting Crucial DNA Repair Pathways in Multiple Myeloma","volume":"26","author":"Patel","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2141.2010.08088.x","article-title":"Non-Homologous End-Joining Gene Profiling Reveals Distinct Expression Patterns Associated with Lymphoma and Multiple Myeloma","volume":"149","author":"Roddam","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1093\/hmg\/ddm273","article-title":"Variation in DNA Repair Genes XRCC3, XRCC4, XRCC5 and Susceptibility to Myeloma","volume":"16","author":"Hayden","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1182\/blood.V120.21.2932.2932","article-title":"Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker","volume":"120","author":"Calimeri","year":"2012","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/jmg.39.12.900","article-title":"Genetic Variants of NHEJ DNA Ligase IV Can Affect the Risk of Developing Multiple Myeloma, a Tumour Characterised by Aberrant Class Switch Recombination","volume":"39","author":"Roddam","year":"2002","journal-title":"J. Med. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41467-021-21386-y","article-title":"Targeting NSD2-Mediated SRC-3 Liquid-Liquid Phase Separation Sensitizes Bortezomib Treatment in Multiple Myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1038\/onc.2016.116","article-title":"MMSET\/WHSC1 Enhances DNA Damage Repair Leading to an Increase in Resistance to Chemotherapeutic Agents","volume":"35","author":"Shah","year":"2016","journal-title":"Oncogene"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Saitoh, T., and Oda, T. (2021). DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment. Cancers, 13.","DOI":"10.3390\/cancers13030504"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/blood-2004-11-4286","article-title":"The FA\/BRCA Pathway Is Involved in Melphalan-Induced DNA Interstrand Cross-Link Repair and Accounts for Melphalan Resistance in Multiple Myeloma Cells","volume":"106","author":"Chen","year":"2005","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/ijc.22411","article-title":"Polymorphisms in the Genes ERCC2, XRCC3 and CD3EAP Influence Treatment Outcome in Multiple Myeloma Patients Undergoing Autologous Bone Marrow Transplantation","volume":"120","author":"Vangsted","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/carcin\/bgh187","article-title":"DNA Mismatch Repair Pathway Defects in the Pathogenesis and Evolution of Myeloma","volume":"25","author":"Velangi","year":"2004","journal-title":"Carcinogenesis"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/362652a0","article-title":"Defective Mismatch Binding and a Mutator Phenotype in Cells Tolerant to DNA Damage","volume":"362","author":"Branch","year":"1993","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1080\/10428194.2018.1427862","article-title":"Heterochronous Occurrence of Microsatellite Instability in Multiple Myeloma\u2014An Implication for a Role of Defective DNA Mismatch Repair in Myelomagenesis","volume":"59","author":"Miyashita","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/35009138","article-title":"Interplay of P53 and DNA-Repair Protein XRCC4 in Tumorigenesis, Genomic Stability and Development","volume":"404","author":"Gao","year":"2000","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mrfmmm.2008.10.019","article-title":"Impaired NHEJ Function in Multiple Myeloma","volume":"660","author":"Yang","year":"2009","journal-title":"Mutat. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s00439-022-02462-9","article-title":"Fanconi Anemia: Current Insights Regarding Epidemiology, Cancer, and DNA Repair","volume":"141","author":"Peake","year":"2022","journal-title":"Hum. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.18632\/oncotarget.1740","article-title":"A DNA Repair Pathway Score Predicts Survival in Human Multiple Myeloma: The Potential for Therapeutic Strategy","volume":"5","author":"Kassambara","year":"2014","journal-title":"Oncotarget"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"Del(17p) without TP53 Mutation Confers a Poor Prognosis in Intensively Treated Newly Diagnosed Patients with Multiple Myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.3324\/haematol.2017.168872","article-title":"The Level of Deletion 17p and Bi-Allelic Inactivation of TP53 Has a Significant Impact on Clinical Outcome in Multiple Myeloma","volume":"102","author":"Thanendrarajan","year":"2017","journal-title":"Haematologica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High Subclonal Fraction of 17p Deletion Is Associated with Poor Prognosis in Multiple Myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A High-Risk, Double-Hit, Group of Newly Diagnosed Myeloma Identified by Genomic Analysis","volume":"33","author":"Walker","year":"2018","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1182\/bloodadvances.2018028530","article-title":"Impact of Acquired Del(17p) in Multiple Myeloma","volume":"3","author":"Lakshman","year":"2019","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Flynt, E., Bisht, K., Sridharan, V., Ortiz, M., Towfic, F., and Thakurta, A. (2020). Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma. Cells, 9.","DOI":"10.3390\/cells9020287"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.V100.1.224","article-title":"Repair of DNA Interstrand Crosslinks as a Mechanism of Clinical Resistance to Melphalan in Multiple Myeloma","volume":"100","author":"Spanswick","year":"2002","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2005.07.385","article-title":"Extent of Damage and Repair in the P53 Tumor-Suppressor Gene after Treatment of Myeloma Patients with High-Dose Melphalan and Autologous Blood Stem-Cell Transplantation Is Individualized and May Predict Clinical Outcome","volume":"23","author":"Dimopoulos","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3324\/haematol.11435","article-title":"Melphalan-Induced DNA Damage in Vitro as a Predictor for Clinical Outcome in Multiple Myeloma","volume":"92","author":"Dimopoulos","year":"2007","journal-title":"Haematologica"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2016-01-691618","article-title":"DNA Repair of Myeloma Plasma Cells Correlates with Clinical Outcome: The Effect of the Nonhomologous End-Joining Inhibitor SCR7","volume":"128","author":"Gkotzamanidou","year":"2016","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/bjc.2014.410","article-title":"Chromatin Structure, Transcriptional Activity and DNA Repair Efficiency Affect the Outcome of Chemotherapy in Multiple Myeloma","volume":"111","author":"Gkotzamanidou","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Herrero, A.B., and Guti\u00e9rrez, N.C. (2017). Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00098"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1038\/bcj.2015.46","article-title":"Targeting the Pim Kinases in Multiple Myeloma","volume":"5","author":"Keane","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1038\/bcj.2016.73","article-title":"Pim2 Is Important for Regulating DNA Damage Response in Multiple Myeloma Cells","volume":"6","author":"Ramachandran","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Zhao, C., Yang, D., Ye, Y., Chen, Z., Sun, T., Zhao, J., Zhao, K., and Lu, N. (2021). Inhibition of Pim-2 Kinase by LT-171-861 Promotes DNA Damage and Exhibits Enhanced Lethal Effects with PARP Inhibitor in Multiple Myeloma. Biochem. Pharmacol., 190.","DOI":"10.1016\/j.bcp.2021.114648"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1158\/0008-5472.CAN-05-4186","article-title":"The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent That Overcomes Drug Resistance","volume":"66","author":"Maiso","year":"2006","journal-title":"Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2010.06.026","article-title":"The Histone Deacetylase Inhibitor LBH589 Enhances the Anti-Myeloma Effects of Chemotherapy in Vitro and in Vivo","volume":"35","author":"Sanchez","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Gkotzamanidou, M., Terpos, E., Dimopoulos, M.A., and Souliotis, V.L. (2022). The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415671"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1096\/fj.06-7859rev","article-title":"Phosphatase-Mediated Crosstalk between MAPK Signaling Pathways in the Regulation of Cell Survival","volume":"22","author":"Junttila","year":"2008","journal-title":"FASEB J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The Protein Kinase Complement of the Human Genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14728222.2011.645805","article-title":"Targeting the MAPK-RAS-RAF Signaling Pathway in Cancer Therapy","volume":"16","author":"Santarpia","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.cels.2022.10.003","article-title":"Systematic Analysis of the MAPK Signaling Network Reveals MAP3K-Driven Control of Cell Fate","volume":"13","author":"Peterson","year":"2022","journal-title":"Cell Syst."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1152\/physrev.00028.2011","article-title":"Mammalian MAPK Signal Transduction Pathways Activated by Stress and Inflammation: A 10-Year Update","volume":"92","author":"Kyriakis","year":"2012","journal-title":"Physiol. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1038\/onc.2008.219","article-title":"Loss of Human Scribble Cooperates with H-Ras to Promote Cell Invasion through Deregulation of MAPK Signalling","volume":"27","author":"Dow","year":"2008","journal-title":"Oncogene"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/jcp.26042","article-title":"The Roles of Signaling Pathways in Bone Repair and Regeneration","volume":"233","author":"Majidinia","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Bolli, N., Genuardi, E., Ziccheddu, B., Martello, M., Oliva, S., and Terragna, C. (2020). Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00189"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The Molecular Make up of Smoldering Myeloma Highlights the Evolutionary Pathways Leading to Multiple Myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic Classification and Individualized Prognosis in Multiple Myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of Genomic Evolution and Mutational Profiles in Multiple Myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients with Newly Diagnosed Myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1038\/s41375-018-0103-3","article-title":"Whole-Genome Sequencing of Multiple Myeloma Reveals Oncogenic Pathways Are Targeted Somatically through Multiple Mechanisms","volume":"32","author":"Hoang","year":"2018","journal-title":"Leukemia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted Sequencing of Refractory Myeloma Reveals a High Incidence of Mutations in CRBN and Ras Pathway Genes","volume":"128","author":"Mai","year":"2016","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The Genetic Architecture of Multiple Myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.apsb.2019.03.002","article-title":"Targeting the Untargetable KRAS in Cancer Therapy","volume":"9","author":"Liu","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"102070","DOI":"10.1016\/j.ctrv.2020.102070","article-title":"KRAS: From Undruggable to a Druggable Cancer Target","volume":"89","author":"Uprety","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of Novel Mutational Drivers Reveals Oncogene Dependencies in Multiple Myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/oncsis.2017.36","article-title":"Molecular Signaling in Multiple Myeloma: Association of RAS\/RAF Mutations and MEK\/ERK Pathway Activation","volume":"6","author":"Xu","year":"2017","journal-title":"Oncogenesis"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2013-05-504340","article-title":"Mutation of NRAS but Not KRAS Significantly Reduces Myeloma Sensitivity to Single-Agent Bortezomib Therapy","volume":"123","author":"Mulligan","year":"2014","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Haque, E., \u015amiech, M., \u0141uczy\u0144ska, K., Bouchard, M.F., Viger, R., Kono, H., Pierzcha\u0142a, M., and Taniguchi, H. (2021). NRF2 DLG Domain Mutations Identified in Japanese Liver Cancer Patients Affect the Transcriptional Activity in HCC Cell Lines. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105296"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/annonc\/mdv112","article-title":"Early Tumor Shrinkage and Depth of Response Predict Long-Term Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line Chemotherapy plus Bevacizumab: Results from Phase III TRIBE Trial by the Gruppo Oncologico Del Nord Ovest","volume":"26","author":"Cremolini","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1158\/1078-0432.CCR-19-1507","article-title":"BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-Term Follow-up of Patients with Multiple Myeloma","volume":"26","author":"Boyle","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/onc.2015.329","article-title":"Stamping out RAF and MEK1\/2 to Inhibit the ERK1\/2 Pathway: An Emerging Threat to Anticancer Therapy","volume":"35","author":"Mandal","year":"2016","journal-title":"Oncogene"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/leu.2015.208","article-title":"Inhibiting MEK in MAPK Pathway-Activated Myeloma","volume":"30","author":"Heuck","year":"2016","journal-title":"Leukemia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"101065","DOI":"10.1016\/j.currproblcancer.2024.101065","article-title":"Targeting MEK in Non-Small Cell Lung Cancer","volume":"49","author":"Lara","year":"2024","journal-title":"Curr. Probl. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1158\/1078-0432.CCR-15-1076","article-title":"A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1\/2 Inhibitor, in Relapsed\/Refractory Multiple Myeloma","volume":"22","author":"Holkova","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clml.2022.10.006","article-title":"Cobimetinib Alone and Plus Venetoclax with\/without Atezolizumab in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"23","author":"Schjesvold","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-135845","article-title":"Safety and Preliminary Efficacy Results from a Phase Ib\/II Study of Cobimetinib as a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Schjesvold","year":"2020","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","article-title":"Targeting the BRAF V600E Mutation in Multiple Myeloma","volume":"3","author":"Andrulis","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/hon.2353","article-title":"Vemurafenib in Combination with Cobimetinib in Relapsed and Refractory Extramedullary Multiple Myeloma Harboring the BRAF V600E Mutation","volume":"35","author":"Mey","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/8821415","article-title":"Rapid Response in a Patient with Relapsed\/Refractory Multiple Myeloma Treated with BRAF\/MEK Inhibitors","volume":"2020","author":"Otieno","year":"2020","journal-title":"Case Rep. Hematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood.2022017789","article-title":"A Phase 2 Clinical Trial of Combined BRAF\/MEK Inhibition for BRAFV600E-Mutated Multiple Myeloma","volume":"141","author":"Giesen","year":"2023","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-142600","article-title":"Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed\/Refractory Multiple Myeloma (RrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial","volume":"136","author":"Raab","year":"2020","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S1470-2045(20)30464-2","article-title":"Intermittent Schedules of the Oral RAF-MEK Inhibitor CH5126766\/VS-6766 in Patients with RAS\/RAF-Mutant Solid Tumours and Multiple Myeloma: A Single-Centre, Open-Label, Phase 1 Dose-Escalation and Basket Dose-Expansion Study","volume":"21","author":"Guo","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/onc.2009.403","article-title":"Sorafenib, a Dual Raf Kinase\/Vascular Endothelial Growth Factor Receptor Inhibitor Has Significant Anti-Myeloma Activity and Synergizes with Common Anti-Myeloma Drugs","volume":"29","author":"Ramakrishnan","year":"2010","journal-title":"Oncogene"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10637-013-0004-2","article-title":"Phase 1 Study of Sorafenib in Combination with Bortezomib in Patients with Advanced Malignancies","volume":"31","author":"Kumar","year":"2013","journal-title":"Investig. New Drugs"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hon.2043","article-title":"Sorafenib in Patients with Refractory or Recurrent Multiple Myeloma","volume":"31","author":"Yordanova","year":"2013","journal-title":"Hematol. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1182\/blood.V108.11.3580.3580","article-title":"Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM)","volume":"108","author":"Siegel","year":"2006","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1158\/1078-0432.CCR-10-0469","article-title":"Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma","volume":"16","author":"Mateos","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting Oncogenic Raf Protein-Serine\/Threonine Kinases in Human Cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_120","first-page":"665","article-title":"Drug Resistance in Targeted Cancer Therapies with RAF Inhibitors","volume":"4","author":"Degirmenci","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1634\/theoncologist.2015-0055","article-title":"Phase II Study of Sorafenib and Bortezomib for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma","volume":"20","author":"Rao","year":"2015","journal-title":"Oncologist"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1182\/blood-2008-05-159392","article-title":"Interruption of the Ras\/MEK\/ERK Signaling Cascade Enhances Chk1 Inhibitor-Induced DNA Damage in Vitro and in Vivo in Human Multiple Myeloma Cells","volume":"112","author":"Dai","year":"2008","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.2174\/092986711798194388","article-title":"Extracellular Signal-Regulated Kinases Modulate DNA Damage Response\u2014A Contributing Factor to Using MEK Inhibitors in Cancer Therapy","volume":"18","author":"Wei","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"14951","DOI":"10.1002\/jcp.28334","article-title":"RAS\/MAPK Signaling Functions in Oxidative Stress, DNA Damage Response and Cancer Progression","volume":"234","author":"Rezatabar","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Wang, X., Martindale, J.L., Liu, Y., and Holbrook, N.J. (1998). The Cellular Response to Oxidative Stress: Influences of Mitogen-Activated Protein Kinase Signalling Pathways on Cell Survival. Biochem. J., 333.","DOI":"10.1042\/bj3330291"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"22173","DOI":"10.1074\/jbc.272.35.22173","article-title":"Fas- or Ceramide-Induced Apoptosis Is Mediated by a Rac1-Regulated Activation of Jun N-Terminal Kinase\/P38 Kinases and GADD153","volume":"272","author":"Brenner","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_127","first-page":"1007","article-title":"Cisplatin-Induced Activation of Mitogen-Activated Protein Kinases in Ovarian Carcinoma Cells: Inhibition of Extracellular Signal-Regulated Kinase Activity Increases Sensitivity to Cisplatin","volume":"5","author":"Persons","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"39435","DOI":"10.1074\/jbc.M004583200","article-title":"Requirement for ERK Activation in Cisplatin-Induced Apoptosis","volume":"275","author":"Wang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0021-9258(17)42175-2","article-title":"Cellular Responses to Cisplatin. The Roles of DNA-Binding Proteins and DNA Repair","volume":"269","author":"Chu","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s002800100318","article-title":"Regulation of P53 Target Gene Expression by Cisplatin-Induced Extracellular Signal-Regulated Kinase","volume":"48","author":"Dehaan","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0092-8674(00)80416-X","article-title":"DNA Damage-Induced Phosphorylation of P53 Alleviates Inhibition by MDM2","volume":"91","author":"Shieh","year":"1997","journal-title":"Cell"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1073\/pnas.150024397","article-title":"Sustained Activation of Ras\/Raf\/Mitogen-Activated Protein Kinase Cascade by the Tumor Suppressor P53","volume":"97","author":"Lee","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"12710","DOI":"10.1074\/jbc.M111598200","article-title":"ERK Activation Mediates Cell Cycle Arrest and Apoptosis after DNA Damage Independently of P53","volume":"277","author":"Tang","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1038\/onc.2013.344","article-title":"Sirtuins in Stress Response: Guardians of the Genome","volume":"33","author":"Vaquero","year":"2014","journal-title":"Oncogene"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1182\/blood-2015-06-649970","article-title":"Evidence for a Role of the Histone Deacetylase SIRT6 in DNA Damage Response of Multiple Myeloma Cells","volume":"127","author":"Cea","year":"2015","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Jones, E.V., Dickman, M.J., and Whitmarsh, A.J. (2007). Regulation of P73-Mediated Apoptosis by c-Jun N-Terminal Kinase. Biochem. J., 405.","DOI":"10.1042\/BJ20061778"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1038\/sj.onc.1209737","article-title":"Cisplatin Induces PKB\/Akt Activation and P38(MAPK) Phosphorylation of the EGF Receptor","volume":"25","author":"Levitzki","year":"2006","journal-title":"Oncogene"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.4161\/cc.6.19.4741","article-title":"P18(Hamlet) Mediates Different P53-Dependent Responses to DNA-Damage Inducing Agents","volume":"6","author":"Lafarga","year":"2007","journal-title":"Cell Cycle"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ijc.20522","article-title":"Long-Term Activation of SAPK\/JNK, P38 Kinase and Fas-L Expression by Cisplatin Is Attenuated in Human Carcinoma Cells That Acquired Drug Resistance","volume":"112","author":"Brozovic","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/emmm.201302732","article-title":"Inhibition of P38 MAPK Sensitizes Tumour Cells to Cisplatin-Induced Apoptosis Mediated by Reactive Oxygen Species and JNK","volume":"5","author":"Pereira","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/toxsci\/kfp145","article-title":"Inhibition of P38-MAPK Potentiates Cisplatin-Induced Apoptosis via GSH Depletion and Increases Intracellular Drug Accumulation in Growth-Arrested Kidney Tubular Epithelial Cells","volume":"111","author":"Quiroga","year":"2009","journal-title":"Toxicol. Sci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00432-007-0278-x","article-title":"Bendamustine Induces G2 Cell Cycle Arrest and Apoptosis in Myeloma Cells: The Role of ATM-Chk2-Cdc25A and ATM-P53-P21-Pathways","volume":"134","author":"Gaul","year":"2008","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1042\/bj3260061","article-title":"Sustained Activation of Extracellular-Signal-Regulated Kinase 1 (ERK1) Is Required for the Continued Expression of Cyclin D1 in G1 Phase","volume":"326","author":"Weber","year":"1997","journal-title":"Biochem. J."},{"key":"ref_144","first-page":"845","article-title":"Biphasic and Synergistic Activation of P44mapk (ERK1) by Growth Factors: Correlation between Late Phase Activation and Mitogenicity","volume":"6","author":"Meloche","year":"1992","journal-title":"Mol. Endocrinol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.cub.2006.04.044","article-title":"Continuous ERK Activation Downregulates Antiproliferative Genes throughout G1 Phase to Allow Cell-Cycle Progression","volume":"16","author":"Yamamoto","year":"2006","journal-title":"Curr. Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"14903","DOI":"10.1073\/pnas.1008990107","article-title":"The RAF Inhibitor PLX4032 Inhibits ERK Signaling and Tumor Cell Proliferation in a V600E BRAF-Selective Manner","volume":"107","author":"Joseph","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Toress-Collado, A.X., Nazarian, R., and Jazirehi, A.R. (2017). Rescue of Cell Cycle Progression in BRAFV600E Inhibitor-Resistant Human Melanoma by a Chromatin Modifier. Tumour Biol., 39.","DOI":"10.1177\/1010428317721620"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Phong, M.S., Van Horn, R.D., Li, S., Tucker-Kellogg, G., Surana, U., and Ye, X.S. (2010). P38 Mitogen-Activated Protein Kinase Promotes Cell Survival in Response to DNA Damage but Is Not Required for the G2 DNA Damage Checkpoint in Human Cancer Cells. Mol. Cell Biol., 30.","DOI":"10.1128\/MCB.00949-09"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"32553","DOI":"10.1074\/jbc.M803963200","article-title":"The P38 Mitogen-Activated Protein Kinase Augments Nucleotide Excision Repair by Mediating DDB2 Degradation and Chromatin Relaxation","volume":"283","author":"Zhao","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1038\/sj.onc.1206954","article-title":"Small-Molecule Cyclin-Dependent Kinase Modulators","volume":"22","author":"Senderowicz","year":"2003","journal-title":"Oncogene"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/0008-5472.CAN-06-2371","article-title":"Extracellular Signal-Related Kinase Positively Regulates Ataxia Telangiectasia Mutated, Homologous Recombination Repair, and the DNA Damage Response","volume":"67","author":"Golding","year":"2007","journal-title":"Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"16856","DOI":"10.1073\/pnas.1304355110","article-title":"Damage-Induced DNA Replication Stalling Relies on MAPK-Activated Protein Kinase 2 Activity","volume":"110","author":"Bierwirth","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nrm1834","article-title":"MAPKAP Kinases\u2014MKs\u2014Two\u2019s Company, Three\u2019s a Crowd","volume":"7","author":"Gaestel","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/6991\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:04:54Z","timestamp":1760108694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/6991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":153,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ijms25136991"],"URL":"https:\/\/doi.org\/10.3390\/ijms25136991","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}